On March 15, Wang Junzhi, academician of Chinese Academy of engineering and deputy head of the vaccine research and development expert group of the scientific research group, said at the press conference of the joint prevention and control mechanism of the State Council that no mutant strain of the new coronavirus has been found to have a significant impact on the protection rate of the conditional new coronavirus in China.
According to Wang Junzhi, several R & D enterprises have used vaccine immune sera to test and evaluate the cross neutralization ability of several mutant strains collected at home and abroad. The latest report has not found that inactivated vaccines and recombinant protein vaccines have significantly decreased the neutralization activity of mutant strains, including South African strains, and further follow-up studies are needed. The long-term transmission of the virus may produce the accumulation of multiple mutations, which will affect the protection of the vaccine to a certain extent.
In order to effectively deal with the impact of virus mutation, Wang Junzhi said that on the one hand, close and real-time monitoring is needed to collect and determine the virus mutation as soon as possible after it is found, so as to determine its impact on the vaccine in time. On the other hand, the construction of vaccine platform should be strengthened, and the vaccine against the mutant strain should be developed in the shortest time.
In addition, Wang Junzhi said that as we all know, there are 17 new crown vaccines in our country entering the clinical stage, four of which have been conditionally approved, and the other three technical routes are basically in the phase III clinical stage or immediately entering the phase III clinical stage. We are very concerned about the progress in the future.
Wang Junzhi said that for these vaccines, there must be two tasks before they are put on the market. One is whether the safety and effectiveness data of phase III clinical trials meet the requirements. The other is to complete the validation of commercial scale production process and establish reliable quality standards for control.
Clinical trials need to obtain sufficient clinical research data. There are great difficulties in phase III clinical trials, which are all done abroad. There are many difficulties to overcome.
- THE END -
Reprint please indicate the source: fast technology